Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 22 October 2021, including: a slow start for Biogen, Inc.’s Aduhelm; Johnson & Johnson looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB S.A. faces bimekizumab delays; and progress and setbacks in gene therapy.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Bluebird Spinoff 2seventy Bio Gets Its Own Wings" - Scrip, 19 Oct, 2021.)
(Also see "UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug" - Scrip, 18 Oct, 2021.)
(Also see "The Next Big Thing In Gene Therapy Might Not Be Gene Therapy" - Scrip, 15 Oct, 2021.)